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Abstract 
Purpose: To formulate and characterize nanoparticles containing silybin, and evaluate their activity 
against carbon tetrachloride (CCl4)-induced liver toxicity.   
Methods: Silybin nanoparticles were formulated by o/w emulsion solvent evaporation technique using 
poly-ε-caprolactone as polymer. Four different nanoparticle formulations (NP1, NP2, NP3 and NP4) were 
prepared by varying the drug/polymer ratio. The particles were characterized for particle size, drug 
content and in vitro drug release. The pharmacokinetics and pharmacodynamics of the silybin 
formulations in male Wistar rats were evaluated following i.v. administration, using silybin solution as 
reference. The hepatoprotective activity of the formulations was also determined in a CCl4-treated rat 
model. 
Results: Silybin nanoparticles were successfully prepared using o/w emulsion solvent evaporation 
technique. The nanoparticles sustained the release of the drug both in vitro and in vivo for up to 10 days 
and offered better pharmacokinetic properties than the free drug itself. Intravenous nanoparticulate 
administration reversed serum liver enzyme levels by 95 % compared to only 50 % for the drug solution.  
Conclusion: The developed silybin nanoparticles showed superior pharmacokinetic properties and 
hepatoprotective activity to silybin solution. 
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Non-alcoholic and alcoholic fatty liver, chronic 
hepatitis and hepatic carcinoma all of which 
causes liver fibrosis that results in irreversible 
cirrhosis ultimately death in human beings [1,2]. 
Liver fibrosis is the accumulation of extracellular 
matrix or scar in the liver. There is no standard 
treatment for liver fibrosis [3]. Thus there is a 
need to find effective treatment for fibrosis. The 
ideal antifibrotic therapy would be one that is 
liver-specific, well tolerated when administered 
for prolonged periods of time, effective in 
attenuating excessive collagen deposition 
without affecting normal ECM synthesis, 
effectively delivered and nontoxic to other 
organs[4].   
 
Silybin is one of the oldest drugs for the 
treatment of liver fibrosis and cirrhosis [5]. 
Although it is considered to be ideal for the 
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treatment of liver fibrosis, delivery to the liver still 
needs improvement. The effectiveness of oral 
silybin as a hepatoprotective agent has 
discounted by its poor solubility, low 
bioavailability and low half-life [6]. Sylibin needs 
to be administered daily to achieve its effects. 
Nanosized carriers encapsulating sylibinin with 
size less than 6 µm can be taken up passively 
into Kupffer cells in the liver and can result in 
increased drug concentration in the liver after 
intravenous administration, thus increasing 
therapeutic efficacy. They can result in sustained 
systemic release of sylibin for more than a week, 
depending on various factors, after forming a 
depot in the Kupffer cells. Thus, repeated daily 
administration for sylibin can be avoided. Further, 
oral bioavailability problems with sylibin can be 
avoided since bioavailability is 100 % after 
intravenous administration.  
 
Oxidative stress in Kupffer cells is known to 
initiate the formation of liver fibrosis in many 
diseases and thus antioxidant sylibin levels in 
these cells, if enhanced, can tremendously 
improve therapy with sylibin. Thus, with this type 
of formulation, sustained parenteral release, 
improvement in bioavailability as well as 
enhancement of biochemical protection can be 
achieved. Together, these mechanisms lead to 
increase in effectiveness of therapy. Thus, the 
objective of this study was to prepare 
biodegradable nanoparticles of silybin, and 
evaluate their sustained release characteristics, 
liver targetability and liver protection following 




Silybin and Poly-ε-caprolactone (mol wt,, 14,000) 
were procured from Sigma-Aldrich, Germany. 
Polyvinyl alcohol (PVA, cold-water soluble) was 
procured from Qualikems Fine Chemicals Pvt 
Ltd, New Delhi. Dichloromethane was procured 
from SD Fine Chemicals Ltd, Mumbai, India. All 
other reagents were of analytical grade. A probe 
sonicator (Homogenizer 150 VT), used to 
prepare the nanoparticles, was procured from 
M/S Biologics, Inc USA. A zeta sizer (3000 HAS 
(Malvern Instruments, Malvern, UK) was used to 
measure the particle size. (HPLC (Waters, USA) 
was used to analyze plasma samples while UV-
Visible spectrophotometer (Shimadzu UV-1800, 
Japan) was used to analyze drug loading and 
drug release samples.  A magnetic stirrer (Remi 
Industries, Mumbai, India) was used to facilitate 
evaporation of dichloromethane while an 
ultracentrifuge (Remi, Mumbai) was employed to 
recover the nanoparticles after preparation. Male 
Wistar rats weighing 150 – 180 g were 
purchased from Mahaveer Enterprises, 
Hyderabad., India 
 
Preparation of silybin nanoparticles 
 
Emulsion (o/w) solvent evaporation method was 
employed in the preparation of silybin 
nanoparticles using poly-ε-caprolactone as the 
polymer. Four different nanoparticle formulations 
NP1, NP2, NP3 and NP4 containing drug:polymer 
in the ratio of 1:1, 1:2,1:3 and 1:4, respectively, 
were prepared. For the preparation, silybin (100 
mg) and polycaprolactone (100, 200, 300 or 400 
mg) was dissolved in 15 ml of dichloromethane 
by vortexing. The mixture (organic phase) was 
added drop-wise to 50 ml of 2 % PVA solution 
under probe sonication at 40 w for 12 min to 
obtain a w/o emulsion. This emulsion was placed 
on a magnetic stirrer to ensure complete 
evaporation of dichloromethane, leaving 
nanoparticle suspension. The suspension was 
centrifuged at 10,000 rpm for 20 min, resulting in 
the formation of a pellet at the bottom of the tube. 
This pellet was washed with phosphate buffered 
saline (PBS), re-suspended and again 
centrifuged. The pellet was collected and allowed 
to dry completely. The powdered particles were 
collected, weighed and used for further 
evaluation. 
 
Determination of particle size and charge 
 
The nanoparticles were evaluated for their 
particle size, polydispersity index of size 
distribution and surface charge potential, by 
photon correlation spectroscopy (PCS) using 
Zetasizer 3000 HAS (Malvern Instruments, 
Malvern, UK). The formulations were diluted 
1:1000 with the aqueous phase of the 
formulation to obtain suitable kilo-counts per 
second (kcps). Analysis was performed at 25 °C 
with an angle of detection of 90°. Each 
determination was made in triplicate.  
 
Evaluation of encapsulation efficiency 
 
Encapsulation efficiency (EE) was calculated by 
estimating the amount of unentrapped drug. This 
was found by measuring the absorbance of the 
drug in supernatant, which was obtained after 
centrifugation of the nanoparticle suspension and 
then applying Eq 1. 
 
EE (%) = 100(W1 – W2)/ W1  …………..…… (1) 
                                                
The value obtained from Eq 1 was compared 
with entrapped drug. For this determination, an 
accurately weighed amount of nanoparticles was 
taken in a test tube, dissolved in 
dichloromethane (DCM) and the solvent allowed 
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to evaporate completely. An aliquot of methanol 
(10 ml) was added to the test tube which 
dissolved only the drug. The absorbance of this 
solution was measured and the amount of drug 
encapsulated calculated.  
 
In vitro release study 
 
The in vitro release study was performed in a 
diffusion cell set-up across a dialysis membrane. 
An inverted cylindrical test tube cut to a height of 
8 cm was used as a donor compartment. The 
receiver compartment consisted of 100 ml of 
phosphate buffer (pH 7.4, 37 °C) in a beaker 
placed over a water bath. A dialysis membrane 
which was pre-soaked in warm water for 30 min 
was placed at the lower end of the cylindrical set-
up and the membrane separated the donor 
compartment from the receiver compartment. 
Nanoparticles containing 20 mg of drug was 
suspended into 5 ml of pH 7.4 buffer and placed 
in the donor compartment. The system was 
stirred using a magnetic stirrer and bead. 
Samples (5 ml) were removed from the receiver  
compartment and replaced with the same volume 
of fresh medium immediately. The samples were 




Male Wister rats (weighing 150 – 180 g each) 
were purchased from Mahaveer Enterprises, 
Hyderabad, India, and were maintained in an air-
conditioned room at 22 ± 2 0C and relative 
humidity of 45 – 55 % in a 12/12 h light/dark 
cycle. The animals had free access to standard 
food pellets and water was available ad libitum. 
All the animal experiments were conducted 
according to the guidelines of the Committee for 
the Purpose of Control and Supervision of 
Experiments on Animals (CPCSEA), Chennai, 
India [7] and the study protocol was approved by 
Institutional Animal Ethical Committee of 
Vaagdevi College of Pharmacy, Warangal, India 
(ref no. 1047/ac/07/CPCSEA). International 
guidelines issued by the International Council for 
Laboratory Animal Science were also followed 
[8]. These conditions were maintained 
throughout the duration of the experiment. The 
study was performed in three groups of six rats 
each.  
 
Group 1 received silybin solution containing 
30mg/kg intravenously; Group 2 received NP1 
silybin nanoparticles equivalent to 30 mg/kg of 
drug suspended in normal saline and injected 
intravenously while Group 3 received placebo 
nanoparticles. Blood samples were collected at 
different time intervals over a period of 24 h. For 
the nanoparticle formulations samples were also 
collected days 3, 6 and 9 after administration. 
Drug levels in the plasma samples were 
evaluated by HPLC.  HPLC standard curve for 
the drug in plasma was also generated. The UV 
detection wavelength was 288 nm while the 
mobile phase consisted of methanol: water 
(50:50, v/v). The following pharmacokinetic 
parameters were determined using WinNonlin 
pharmacokinetic data analysis software: 
elimination rate constant (ke), volume of 
distribution (Vd), elimination half-life (t1/2), 
clearance (CL), and area under curve (AUC). 
 
Evaluation of hepatoprotective activity  
 
Carbon tetrachloride (CCl4)-induced liver 
damage model was used in the evaluation of 
hepatoprotective activity. For this purpose 
another set of male Wistar rats were divided into 
five groups each containing 6 rats. Group1 
received normal saline (1 ml/rat) daily for 9 days 
and served as normal control. Group 2 received 
CCl4 (dissolved in 3 times its volume of olive) at 
a dose of 0.7 ml/kg intraperitoneally on days 3, 6 
and 9 and served as toxic control. Group 3 
received the drug solution in a dose of 100 mg/kg 
intravenously daily for 9 days. Group 4 received 
silybin nanoparticle suspension equivalent to 100 
mg/kg of drug intravenously on day 1 while 
Group5 received placebo nanoparticles. All the 
groups received CCl4 at days 1, 3, 6 and 9 of the 
study except normal control.  
 
The animals were anaesthetized on the last day 
of the study and blood was collected by cardiac 
puncture. Plasma was separated from the blood 
samples by centrifugation at 3000 rpm for 15 
min. Hepatoprotective activity was quantified by 
serum glutamate oxaloacetate transaminase 
(SGOT) and serum glutamate pyruvic 
transaminase (SGPT) levels in the plasma. 
Subsequently, their livers were subjected to 
histopathological examination. First, the rats 
were sacrificed at the last day of the study, the 
liver separated carefully and preserved in 
formalin solution, and liver sections were 





The data were expressed as mean± standard 
deviation (SD) and statistical analysis was 
carried out by one-way ANOVA followed by 
Student’s Newman-Keuls test. The level of 
significance used was P < 0.05. The statistical 
software used was Graph Pad Prism, USA, 
versions 4 and 5. 
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Silybin nanoparticles were successfully prepared 
using poly-ε-caprolactone by o/w emulsion 
solvent evaporation method. The mean particle 
size of the nanoparticles ranged from 130 - 430 
nm (Table 1). Mean particle size increased with 
increase in polymer concentration. The 
polydispersity index (PDI) of the nanoparticles 
was < 0.4, indicating that the nanoparticles were 
homogenous in distribution. The zeta potential 
value indicates long term stability. The 
encapsulation efficiency of the nanoparticles 
increased as polymer concentration increased. 
 
In vitro drug release characteristics 
 
In vitro release data, shown in Fig 1, indicates 
that all the formulations sustained drug release 
for over a period of 20 days. A biphasic drug 
release pattern was found, i.e., burst release 
followed by sustained release. In the first 6 hours 
of release, the unencapsulated drug component 
was released. Subsequently, the encapsulated 
drug component was gradually released.  Drug 
release from NP1 was higher than from NP2, 
NP3 and NP4. Log percent cumulative drug 
released, plotted as a function of log time yielded 
curves, the slope of is the diffusional release 
exponent (n). The values of diffusional n were 
0.359, 0.374, 0.420 and 0.450 for NP1, NP2, NP3 
and NP4 respectively, which indicate that drug 
release from all the formulations followed a 
Fickian pattern [9]. 
   
 
Figure 1:  Drug release from silybin nanoparticles (◊= 
NP1, □=NP2, ∆= NP3, ×=NP4) 
 
Pharmacokinetics of the formulations  
 
The retention time of the drug, based HPLC 
studies, was 16.0 and 18.0 min for the two 
isomers of silybin.  The plasma profiles of the 
drug after administration of nanoparticles and i.v. 
solutions are shown in Figure 2. Nanoparticles 
resulted in higher and more prolonged drug 
levels than the drug solution. This was reflected 
by increased area under the curve. The t1/2, AUC 
and Vd of nanoparticle formulation were higher 
than for the drug solution, while clearance (CL) 
was lower than for the free drug (Table 2). All the 
pharmacokinetic parameters obtained for the 
nanoparticles were statistically different from 
those obtained for the drug solution (p < 0.001), 
except Cmax.  
 
 
Figure 2:   Plasma concentration-time curve of silybin 
following i.v. administration to rats (♦ =         
nanoparticles, □ = solution) 
 
Hepatoprotective activity  
 
Table 3 shows hepatoprotective activity data. 
The administration of CCl4 to the animals 
resulted in a marked increase in SGPT and 
SGOT activities, indicating increased toxicity, but 
this was mitigated in the animals treated with 
silybin formulations. The reduction in toxicity was 
statistically significant at p < 0.001 for both 
sylibinin formulations and sylibin solution.  
      Table 1:  Particle size, charge, PDI and encapsulation efficiency of silybin nanoparticles 
             








NP1 135±3 0.13 -31±3 91.0 
NP2 220±2 0.14 -36±3 92.6 
NP3 310±2 0.20 -34±3 94.9 
NP4 426±1 0.35 -37±3 95.3 
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Table 2:  Pharmacokinetic parameters for silybin 








Cmax (µg/ml) 4.7± 0.2 4.3±0.1 
Ke (h-1) 0.316±0.009 0.00791±0.00016*** 
t1/2(h) 2.19±0.10 87.6±1.3*** 
Vd(L) 0.893±0.04 0.976±0.007*** 
Clearance( L/h) 0.282±0.001 0.00715±0.00012*** 
AUC0-∞(µg.h/ml) 15.42±0.24 600.8±0.8*** 
*** p < 0.001, ** p < 0.01, *p < 0.05, compared with silybin i.v. 
solution. 
 
Table 3:  Effect of silybin formulations on enzyme 
levels in rats with carbon tetrachloride (CCl4) -induced 















































*** p < 0.001, ** p < 0.01,* p < 0.05 compared with CCl4 
group 
 
However, the drug nanoparticles completely 
reversed the elevated levels of SGOT and 
SGPT. 
 
The photomicrographs in Fig 3 display the 
histological changes in the liver of the animals 
following administration of the drug-loaded 
nanoparticles. The histological profile of the 
control animals showed normal hepatic 
architecture with distinct hepatic cells, well-
presented cytoplasm sinusoidal spaces and 
central vein. However, there was disorganization 
of normal cells with intense centrilobular necrosis 
following CCl4 intoxication. Moderate 
accumulation of fatty lobules and cellular 
necrosis were observed in the animals treated 
with silybin solution. However, the nanoparticle 
formulation exhibited strong protection against 
CCl4-induced liver damage, as evidenced by the 
presence of normal hepatic cords, well-defined 
cytoplasm and absence of necrosis. 
Furthermore, the body weights of the rats which 
fell significantly after CCl4 treatment were 





In recent years, various new drug carrier systems 
in the micro- and nanometer size range have 
been generated to improve drug delivery. Among 
them, nanoparticles have certain advantages 
such as a maximal load of the drug and a long 
shelf life. Furthermore, their body distribution and 
permeability in tissues can be controlled by size 
and surface properties [10].  Previously, we 
demonstrated the enhanced liver protection of 
curcumin, curcumin analogues and piperine, 
using kupffer cell (KC)-targeted nanoparticle and 
liposomal formulations, and sustained release 
intraperitoneal microspheres [11-13].  Silybin, a 
natural antioxidant, has long been used for the 
treatment of chronic liver diseases. The 
effectiveness of silybin as a liver disease remedy 
was discounted by its poor solubility and low 
bioavailability. It offers low bioavailability due to 
high first pass metabolism, low t1/2 and results in 
patient non compliance due to repeated dosing. 
Consequently, insufficient concentrations of 
drugs may accumulate in the target cells. 
Further, uptake into non-target cells may lead to 
significant side-effects.    Thus we made an 
attempt to deliver silybin nanoparticles to its 
target site through bypassing oral route. It can be 
administered systemically to offer liver protection 
in a variety of diseases. It can also be targeted to 
KC and its delivery into these cells can be 
enhanced with silybin encapsulated in the 
particulate systems and further improving the 
therapy.  
 
To achieve the aims of this study, silybin 
nanoparticles have been prepared using 
emulsion solvent evaporation technique. Four 
different formulations NP1, NP2, NP3 and NP4 
were prepared. Particle size and entrapment 
efficiency of silybin nanoparticles increased with 
increase in polymer content. This may be due to 
the availability of more polymer to coat the drug. 
Increase in polymer content also delayed drug 
release due to increase in particle size and 
hence reduced surface area available for drug 
release. Drug release was highest from NP1 due 
to because it had the polymer content and this 
has the effect of retarding drug release as a 
result of increased particle size and reduced 
surface area available for drug release. 
Formulation NP1 was used as the optimized 
formulation for hepatoprotective test because of 
its lower particle size and polydispersity index 
(PDI), and good release profile. This particle size 
favors uptake into all the liver cells responsible 
for the formation of liver fibrosis [14]. Higher 
uptake of particles into KC occurs by passive 
targeting.     
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          a)  Normal liver                                            b)    CCl4 treated liver 
                            
      c) Liver treated with silybin solution                   d) Liver treated with Silybin nanoparticles 
 
       Figure 3:  Histopathological profile of rat liver following nanoparticle administration 
 
NP1 sustained drug release for up to 10 days in 
vivo and offered better pharmacokinetic 
properties than the drug in solution form. 
Elimination rate constant and clearance than for 
the drug solution. Furthermore, area under the 
curve (AUC) was several-fold than for the 
solution. This suggests reduction in drug 
elimination and metabolism with nanoparticle 
formulation administration.  
 
Carbon tetrachloride, a known hepatotoxin, is a 
commonly used model for hepatoprotective drug 
screening, and the severity of the liver damage is 
measured by the levels of elevated cytoplasmic 
enzymes (SGOT and SGPT) in circulation [15]. 
The hepatocellular damage induced by CCl4 is 
due to its metabolite, trichloromethyl free radical 
(CCl3) that binds to lipoprotein and leads to 
peroxidation of the lipids of the endoplasmic 
reticulum [16] by the action of the mixed function 
of the cytochrome P450 oxygenase system. This 
free radical, which is initially relatively unreactive 
when formed initially, reacts very rapidly with 
oxygen to yield a highly reactive trichloromethyl 
peroxy radical (CCl3OO). Both radicals are 
capable of binding to proteins or abstracting a 
hydrogen atom from an unsaturated lipid, thus 
accelerating lipid peroxidation.  Expectedly, 
SGOT and SGPT levels were higher in CCl4-
treated animals due to tissue damage caused by 
CCl4 which results in the release of the enzymes 
in to the blood stream.  Upon administration, 
silybin reduced elevated enzyme levels. Reversal 
of liver toxicity was greater for nanoparticle 
formulation than for the drug solution form 
probably because the nanosized particles were 
instantly taken up by KC as well as by several 
other liver cells. As a result, the drug becomes 
accumulated in the liver cells and is 
subsequently released at the cellular level to 
achieve better hepatoprotection.  
 
Overall, the findings of this study suggest that the 
developed nanoparticle formulation may be 
useful in the treatment of cirrhosis and fibrosis 
with silybin. It is likely that these results can be 
extrapolated to other drugs, suggesting the 
probability of nanoparticulate passive targeting of 
drugs to the liver, including for the treatment 




Silybin nanoparticles can be suitably prepared by 
emulsion solvent evaporation technique using 
polycaprolactone as a biodegradable polymer. 
The particles showed good encapsulation 
efficiency and sustained drug release both in 
Bonepally et al  
Trop J Pharm Res, February 2013;12 (1): 
 
6 
vitro and in vivo. Silybin nanoparticles offer an 
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